Export

EN
FR
Dacarbazine
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.1. Cytotoxic medicines
ATC codes: L01AX04
EMLc
Indication
Hodgkin lymphoma ICD11 code: 2C10.Z
INN
Dacarbazine
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 100 mg in vial powder for injection ; 200 mg in vial powder for injection
EML status history
First added in 1989 (TRS 796)
Changed in 2002 (TRS 914)
Changed in 2007 (TRS 950)
Changed in 2011 (TRS 965)
Changed in 2015 (TRS 994)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Dacarbazine
DrugBank
Dacarbazine
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional strength formulation of dacarbazine powder for injection (200 mg in vial) to the EML and EMLc.
Expert Committee report